O'Brien, Maureen M <br/><br/>
Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group.  [electronic resource] 

 -  Pediatric blood & cancer  May 2010 
 - 694-702 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1545-5017 
<br/><br/><label>Standard No.: </label>10.1002/pbc.22366  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>ATP Binding Cassette Transporter, Subfamily B, Member 1--antagonists & inhibitors<br/>Adolescent<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Child<br/>Child, Preschool<br/>Cyclosporins--administration & dosage<br/>Drug Resistance, Multiple<br/>Drug-Related Side Effects and Adverse Reactions<br/>Etoposide--administration & dosage<br/>Female<br/>Humans<br/>Leukemia, Myeloid, Acute--drug therapy<br/>Male<br/>Maximum Tolerated Dose<br/>Mitoxantrone--administration & dosage<br/>Precursor Cell Lymphoblastic Leukemia-Lymphoma--drug therapy<br/>Recurrence<br/>Salvage Therapy<br/>Young Adult